This study is for adults with a specific type of advanced lung cancer (EGFR-mutant non-squamous NSCLC) where standard targeted pills have stopped working. It aims to see if adding a new drug called AK112 to standard chemotherapy helps control the cancer better and helps people li…
Phase: PHASE3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC